Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma

Reuben White, Emily Pulford, David J. Elliot, Lauren A. Thurgood, Sonja Klebe

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Malignant pleural mesothelioma (MPM) is a devastating malignancy with a prognosis of <12 months. Even with bans on the use of asbestos in most Western countries, the incidence is still increasing due to the long latency periods between exposure and development of the disease. Diagnosis is often delayed due to invasive biopsies and lack of distinguishable markers. Patients frequently present with pleural effusions months to years before a radiologically detectable mass appears. This study aimed to investigate the proteome of pleural effusions taken from patients with MPM, adenocarcinoma and benign conditions in an attempt to identify a biomarker for early diagnosis. We identified several proteins that may be possible targets and warrant further investigation. Due to the predominance of up regulated proteins involved in VEGF signalling in MPM, we analysed VEGFA levels in effusions and found a strong correlation between VEGFA levels and survival in MPM.

Original languageEnglish
Pages (from-to)374-382
Number of pages9
JournalJournal of Proteomics
Publication statusPublished - 10 Feb 2019


  • Lung adenocarcinoma
  • Mesothelioma
  • Pleural effusions
  • Quantitative proteomics


Dive into the research topics of 'Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this